Ticagrelor Market Analysis

The trajectory of market growth for ticagrelor is significantly influenced by the increasing aging population, particularly in the Asia-Pacific region and other developing nations. The aging demographic is more susceptible to chronic ailments such as arthritis, kidney diseases, and cardiovascular diseases, thus acting as a catalyst for the expansion of the market. This demographic shift is particularly pronounced in China, where, according to the China National Committee on Aging, the number of individuals aged 60 and above reached 185 million in 2014, constituting 15.7% of the population. Projections suggest that this figure is anticipated to surge to 487 million by 2053, representing 36.5% of the population. The growing geriatric population is a major driving force behind the market growth in the Asia-Pacific region and similar trends are observed in other developing nations.

Globally, data from the United Nations' World Population Prospects reveals that approximately 962 million individuals aged 60 and above were present worldwide as of 2017, constituting about 13% of the global population. The World Health Organization (WHO) estimates that this demographic segment will nearly double from 12% to 22% by the year 2050. In the United States, it is projected that more than 20% of the total population will be aged 65 or over by 2030. Similarly, the United Nations predicts that Asia will house around 857,040 individuals aged 60 and above by 2050. This exponential rise in the older population is directly correlated with the ticagrelor market, as the elderly are more susceptible to injuries and various health conditions such as gastrointestinal problems, orthopedic diseases, and other ailments stemming from compromised immunity. Consequently, this demographic shift increases the frequency of hospital visits among the elderly, contributing to the demand for medications like ticagrelor.

the expanding aging population, particularly in regions like Asia-Pacific, is a pivotal factor steering the growth of the ticagrelor market. The prevalence of chronic diseases among the elderly, coupled with the projected surge in the aging demographic globally, underscores the significance of pharmaceutical interventions like ticagrelor. As the world witnesses a substantial increase in the older population, the demand for treatments addressing the unique healthcare needs of this demographic is expected to escalate, positioning ticagrelor as a crucial player in addressing the health challenges associated with an aging population.